Compare GSK plc (GSK) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Consumer Staples Select Sector SPDR Fund — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Consumer Staples Select Sector SPDR Fund trades at $83.37 (market cap $13.50B). The key difference: GSK plc is far larger — about 6.8× Consumer Staples Select Sector SPDR Fund's market cap, and GSK plc pays a 3.9% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| GSK | XLP | |
|---|---|---|
Market Cap | $91.88B | $13.50B |
Volume | 7,730,529 | 14,599,953 |
Sector | Health | — |
52-Week High | $61.18 | $90.00 |
52-Week Low | $43.24 | $75.61 |
Typical Hold Time | 93 Days | 72 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
XLP trades at $83.43, up 2.12% with strong bullish technical signals from moving averages and oscillators. The ETF shows defensive sector strength, gaining 6.6% year-to-date while consumer discretionary lags. Analyst consensus is unanimously bullish with 100% buy ratings. Recent dividend declaration of $0.54 payable in September 2026 adds income appeal.
Outlook remains positive given consumer staples' defensive characteristics amid economic uncertainty. Key opportunities include sector outperformance and dividend yield, while risks center on interest rate sensitivity and potential consumer spending slowdown. The ETF's low 0.08% expense ratio provides cost advantage over peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
